US FDA Expands Approval for Travere's Drug for Rare Kidney Disease

FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients - Travere Therapeut

Travere says FILSPARI gains full FDA approval for FSGS, expanding treatment scope and showing strong proteinuria reduction in trials.

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS

FILSPARI is the first and only approved medicine for this rare kidney disorder and leading cause of kidney failure

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan) in FSGS (2026-04-14)

-Ligand Pharmaceuticals Incorporated today announced that its partner Travere Therapeutics, Inc. has received approval from the U.S. Food and Drug Administration for FILSPARI ® to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis without nephrotic syndrome. “We congratulate Travere for...

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS

SAN DIEGO--(BUSINESS WIRE)--Apr 13, 2026-

US FDA expands approval for Travere's drug for rare kidney disease

Travere Therapeutics Stock Soars 33% After FDA Approves FILSPARI as First Drug for Rare Kidney Disease FSGS

NEW YORK — Shares of Travere Therapeutics Inc. skyrocketed more than 33% in early trading Tuesday after the U.S. Food and Drug Administration granted full approval for the company's drug FILSPARI to treat focal segmental glomerulosclerosis, a rare and progressive kidney disorder with no prior approved therapies.